First Testosterone Gel Trial to Begin in June

May 31st, 2017

The first of seven multidistrict litigation (MDL) trials involving testosterone therapy gel products begins on June 5, 2017 in the U.S District Court for the Northern District of Illinois.  About 7,000 individual cases have been filed in this MDL. The Plaintiffs allege that over a dozen pharmaceutical companies unethically and aggressively marketed testosterone replacement therapy drugs to treat symptoms of normal male aging. AbbVie Inc. and Abbott Laboratories face most of the claims in the upcoming trials, primarily involving the popular product AndroGel. The pharmaceutical company faces accusations of creating and marketing a condition known as “Low T” to create a need for treatment using AndroGel.  This was done, however, without regard for the known dangers of the product.

The U.S. Food and Drug Administration (FDA) approves testosterone therapy products to treat a medical condition known as hypogonadism, which is the inability of the human body to produce sufficient amounts of testosterone. Diagnosis of this disease requires a blood test and is rare. AbbVie, however, used a marketing campaign that focused on using AndroGel to combat low energy levels, weight gain, and low libido, symptoms that frequently occur in men as they age, unrelated to hypogonadism. The FDA rejected the company’s repeated requests for approval to recommend use of the product for age-related dips in testosterone. As an end run around the FDA, AbbVie provided patients with self-diagnostic tests that relied on answers to simple questions, instead of the comprehensive blood work required to accurately prescribe testosterone gel as a treatment for hypogonadism.

Not only did AbbVie deceive thousands of men into thinking that they had a treatable condition that required the use of their drug, they also failed to adequately warn medical professionals and consumers about the dangers of using AndroGel. In 2014, the National Institute of Health (NIH) completed a study on the records of 55,000 men who had used testosterone therapy. The study showed that the use of testosterone therapy to treat “Low T” in men over the age of 65 doubled the relative risk of heart attack, and more than doubled the risk of heart attack and stroke in men under 65 with a history of heart disease. Other risks associated with use of the product included blood clots, prostate cancer, reduced sperm count, gynecomastia, edema, and high cholesterol. Plaintiffs claim that they were not adequately warned of these dangerous side effects.

The plaintiff in the first MDL trial alleges that he suffered a heart attack just two months after he began his AndroGel treatment. The trial, which begins in just 10 days, is forecasted to last about three weeks and will be followed by six other trials in the coming months. Our experienced lawyers fight for individuals who have been harmed by defective products. If you or a loved one has suffered a heart attack, blood clot, or stroke after testosterone therapy, the attorneys at the Yost Legal Group will investigate your claim. For a free consultation, please call us at 1-800-YOSTLAW. At The Yost Legal Group, there is no fee or expense unless you recover.

AbbVie Hit with $150M Verdict in “Low-T” Trial

The first jury verdict in a series of bellwether trials involving the testosterone treatment AndroGel is in. The jury found that the manufacturer of the gel, AbbVie, should pay $150 million in punitive damages to Oregon resident Jesse Mitchell. After seeing a commercial about AndroGel and using the product for 4 years, Mr. Mitchell suffered a nearly fatal heart attack. He testified that he would not have used the drug if AbbVie had properly warned…

Read More »

FDA Announces Labeling Change for Low Testosterone Medications; Warns of Increased Risk of Heart Attack and Stroke with Use

The Food and Drug Administration (FDA) recently announced that they will be increasing restrictions on the labeling and sale of medication aimed at treating low levels of testosterone in adult men. For years, drug manufacturers have marketed medications such as Androgel, Axiron, and many others, as a “cure” for many of the symptoms associated with the normal aging process of adult men. According to these advertisements, problems such as lowered libido, erectile dysfunction, decreased energy…

Read More »

European Union Agrees with FDA, Testosterone Therapy Is Too Risky for All defective drug lawyers baltimore, product liability, medical malpractice lawyers maryland, low testosterone therapy

The leading Medical Associations in the United States and European Union have reached a consensus on therapies promising to treat low levels of testosterone in older men, a condition also known as “Low-T.” The U.S Food and Drug Administration (FDA) has already issued warnings about the use of Testosterone therapy treatments, advising consumers that the medications significantly raise the risk of serious blood clot and cardiac conditions. The European Union’s European Medicines Agency (EMA) reached…

Read More »

Low Testosterone Therapy is Causing Serious Adverse Reactions

Testosterone lawsuits are being filed throughout the country.  The Yost Legal Group defective drugs lawyers are actively investigating testosterone lawsuits for heart attack, stroke, pulmonary embolism and death. Reliable scientific studies confirm Testosterone supplementation dramatically increases the risk of these side effects in men who are healthy or have a prior heart condition. If your loved one has suffered heart attack, stroke, blood clot or death after initiating testosterone therapy, call the experienced testosterone lawyers…

Read More »